NovaBridge Biosciences (NBP) Cash & Equivalents (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Cash & Equivalents data on file, last reported at $210.6 million in Q4 2025.

• Quarterly Cash & Equivalents rose 208.56% year-over-year to $210.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $210.6 million (up 208.56% YoY) and the FY2025 annual result came in at $210.6 million, up 208.56% from the prior year.
• Cash & Equivalents slipped to $210.6 million in Q4 2025 per NBP's latest filing, from $228.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $737.0 million in Q2 2021 and bottomed at $53.6 million in Q1 2025.
• The 5-year median for Cash & Equivalents is $297.4 million (2023), against an average of $315.8 million.
• The widest annual swing landed in 2021, when Cash & Equivalents soared 233.79%; it then slumped 77.05% in 2024.
• Tracing NBP's Cash & Equivalents over 5 years: stood at $551.1 million in 2021, then slipped by 18.0% to $451.9 million in 2022, then sank by 34.18% to $297.4 million in 2023, then tumbled by 77.05% to $68.3 million in 2024, then soared by 208.56% to $210.6 million in 2025.
• Per Business Quant, the three latest NBP Cash & Equivalents figures stand at $210.6 million (Q4 2025), $228.1 million (Q3 2025), and $165.4 million (Q2 2025).

Peer Comparison